FI970747A0 - Yhdistelmävalmiste käytettäväksi immunologisissa sairauksissa - Google Patents

Yhdistelmävalmiste käytettäväksi immunologisissa sairauksissa

Info

Publication number
FI970747A0
FI970747A0 FI970747A FI970747A FI970747A0 FI 970747 A0 FI970747 A0 FI 970747A0 FI 970747 A FI970747 A FI 970747A FI 970747 A FI970747 A FI 970747A FI 970747 A0 FI970747 A0 FI 970747A0
Authority
FI
Finland
Prior art keywords
immunological diseases
combination preparations
compound
combination
preparations
Prior art date
Application number
FI970747A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI970747A (fi
Inventor
Martin Schoenharting
Stefan Muellner
Peter Zabel
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of FI970747A0 publication Critical patent/FI970747A0/fi
Publication of FI970747A publication Critical patent/FI970747A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI970747A 1994-08-25 1997-02-21 Yhdistelmävalmiste käytettäväksi immunologisissa sairauksissa FI970747A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4430128A DE4430128A1 (de) 1994-08-25 1994-08-25 Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen
PCT/EP1995/003125 WO1996005838A2 (fr) 1994-08-25 1995-08-07 Preparation combinee pour le traitement de maladies immunitaires

Publications (2)

Publication Number Publication Date
FI970747A0 true FI970747A0 (fi) 1997-02-21
FI970747A FI970747A (fi) 1997-02-21

Family

ID=6526515

Family Applications (1)

Application Number Title Priority Date Filing Date
FI970747A FI970747A (fi) 1994-08-25 1997-02-21 Yhdistelmävalmiste käytettäväksi immunologisissa sairauksissa

Country Status (12)

Country Link
US (2) US5990103A (fr)
EP (1) EP0777482B1 (fr)
JP (1) JPH10504550A (fr)
AT (1) ATE208620T1 (fr)
AU (1) AU697311B2 (fr)
DE (2) DE4430128A1 (fr)
DK (1) DK0777482T3 (fr)
ES (1) ES2162937T3 (fr)
FI (1) FI970747A (fr)
MX (1) MX9701385A (fr)
PT (1) PT777482E (fr)
WO (1) WO1996005838A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294350B1 (en) * 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
KR100396171B1 (ko) * 1998-08-10 2003-08-27 아사히 가세이 가부시키가이샤 염산 파수딜의 경구 서방성 제제
US6368815B1 (en) 1999-03-29 2002-04-09 Warner-Lambert Company Screening of molecules that inhibit human phosphodiesterase 4A produced by non-recombinant cell lines
DK1165558T3 (da) * 1999-03-31 2004-02-09 Vernalis Ltd Pyrimido[6,1-a]isoquinolin-4-on-derivater
CA2876779A1 (fr) 2000-05-12 2001-11-22 Genzyme Corporation Modulateurs de marquage du tnf-.alpha.
US7470718B2 (en) * 2000-10-03 2008-12-30 Albert Einstein College Of Medicine Of Yeshiva University Method for treating a demyelinating condition
US20040242565A1 (en) * 2001-09-11 2004-12-02 Yoshinori Toshima Medicinal composition for prevention of or treatment for cerebrovascular disorder and cardiopathy
WO2003030823A2 (fr) * 2001-10-05 2003-04-17 Combinatorx, Incorporated Combinaisons permettant le traitement des troubles inflammatoires
DE10226420A1 (de) * 2002-06-13 2004-01-15 Eucro European Contract Research Gmbh & Co Kg Verfahren zur Behandlung der Artherosklerose
AU2003286555A1 (en) * 2002-10-22 2004-05-13 Harbor-Ucla Research And Education Institute Phosphodiester inhibitors and nitric oxide modulators for treating peyronie's disease, arteriosclerosis and other fibrotic diseases
US8133903B2 (en) * 2003-10-21 2012-03-13 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
US7217718B2 (en) * 2002-11-21 2007-05-15 Genzyme Corporation Induction of immune tolerance
ES2363914T3 (es) * 2002-11-21 2011-08-19 Genzyme Corporation Utilización de un derivado de diamida para inhibir el rechazo crónico de un transplante.
US20040147534A1 (en) * 2003-01-23 2004-07-29 Foote Mary Ann Topical composition and method for treating occlusive wounds
US20040241234A1 (en) * 2003-06-02 2004-12-02 Alpharma, Inc. Controlled release press-coated formulations of water-soluble active agents
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
WO2006054536A1 (fr) * 2004-11-16 2006-05-26 Nippon Shinyaku Co., Ltd. Agent thérapeutique contre la formation de calculs urinaires
US7767710B2 (en) 2005-05-25 2010-08-03 Calosyn Pharma, Inc. Method for treating osteoarthritis
US20060269579A1 (en) * 2005-05-25 2006-11-30 Musculoskeletal Research Llc Compositions for treating osteoarthritis
WO2007139753A2 (fr) * 2006-05-22 2007-12-06 Combinatorx, Incorporated Méthodes et compositions pour le traitement de maladies ou d'affections associées à des taux accrus de protéine c réactive, d'interleukine 6 ou d'interféron gamma
CA2737131A1 (fr) * 2007-09-19 2009-03-26 Zalicus Inc. Regimes therapeutiques pour le traitement de troubles immunoinflammatoires
US20090163440A1 (en) * 2007-09-26 2009-06-25 Waddell David D Ion-Channel Regulator Compositions and Methods of Using Same
CA2709561A1 (fr) * 2007-12-17 2009-06-25 Combinatorx, Incorporated Regimes therapeutiques pour le traitement de troubles immuno-inflammatoires
EP2265334A2 (fr) 2008-02-29 2010-12-29 Concert Pharmaceuticals, Inc. Dérivés de xanthine substitués
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
WO2013013052A1 (fr) 2011-07-19 2013-01-24 Concert Pharmaceuticals, Inc. Dérivés de xanthine substitués
CA2869874A1 (fr) 2012-04-13 2013-10-17 Concert Pharmaceuticals, Inc. Derives de xanthine substituee
CA2981791A1 (fr) 2014-04-18 2015-10-22 Concert Pharmaceuticals, Inc. Methodes de traitement de l'hyperglycemie
US20220204456A1 (en) * 2019-04-30 2022-06-30 Generos Biopharma Ltd. Compound for treating autoimmune skin diseases caused by inflammation, and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU601695B2 (en) * 1985-07-02 1990-09-20 Key Pharmaceuticals, Inc. Method and composition for the treatment of chronic obstructive pulmonary disease
DE3604149A1 (de) * 1986-02-10 1987-08-13 Rentschler Arzneimittel Arzneimittelkombination
EP0493682A3 (en) * 1990-11-30 1992-11-19 Hoechst-Roussel Pharmaceuticals Incorporated Use of xanthines for the preparation of a medicament effective for inhibiting the effects of allograft reaction in humans
EP0490181A1 (fr) * 1990-11-30 1992-06-17 Hoechst-Roussel Pharmaceuticals Incorporated Utilisation de xanthines pour la préparation d'un médicament ayant une activité immunosuppressive
IL99368A (en) * 1991-09-02 1996-01-19 Teva Pharma Preparations for the treatment of psoriasis and atopic dermatitis, which contain the result of xanthine
US5190972A (en) * 1992-01-27 1993-03-02 The University Of Melbourne Method of combatting cyclosporine organ toxicity with prostaglandin analogs
AU669702B2 (en) * 1992-03-04 1996-06-20 Cell Therapeutics, Inc. Enantiomeric hydroxylated xanthine compounds
AU4246793A (en) * 1992-05-13 1993-12-13 Alcon Laboratories, Inc. Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents
US5670506A (en) * 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines

Also Published As

Publication number Publication date
JPH10504550A (ja) 1998-05-06
DE59509848D1 (de) 2001-12-20
AU697311B2 (en) 1998-10-01
ATE208620T1 (de) 2001-11-15
DE4430128A1 (de) 1996-02-29
ES2162937T3 (es) 2002-01-16
WO1996005838A2 (fr) 1996-02-29
PT777482E (pt) 2002-04-29
DK0777482T3 (da) 2002-02-18
EP0777482A1 (fr) 1997-06-11
MX9701385A (es) 1997-05-31
FI970747A (fi) 1997-02-21
US5990103A (en) 1999-11-23
EP0777482B1 (fr) 2001-11-14
US6337325B1 (en) 2002-01-08
WO1996005838A3 (fr) 1996-04-11
AU3382995A (en) 1996-03-14

Similar Documents

Publication Publication Date Title
FI970747A0 (fi) Yhdistelmävalmiste käytettäväksi immunologisissa sairauksissa
AU5296593A (en) Concentrated mouthrinse for efficient delivery of antimicrobials
NZ251320A (en) Bis-aromatic alpha,beta-unsaturated ketones, preparation and use in pharmaceutical compositions
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
NZ227788A (en) Peptide having growth hormone regulatory effects, and compositions
DK0859596T3 (da) Vækstfaktorholdige gelformuleringer
EA199800946A1 (ru) Концентрированный препарат антител
AU9127591A (en) Biologically active bactericidal/permeability-increasing protein fragments
NO910340L (no) Topiske preparater for behandling av menneskenegler.
FI964253A (fi) Kollageenivalmiste vaikuttavien aineiden säädellyksi vapauttamiseksi
EE9800182A (et) PGE-1 sisaldavad lüofiliseeritud liposoomid kasutamiseks erektsioonihäire ravis
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
BR0012006A (pt) Método para evitar inflamações, doenças autoimunes e crescimento de tumor, e, uso de substâncias que suprimem a ativação mediada por ltbr
RS49520B (sr) Antimikrobno aktivne smeše
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
FI964448A0 (fi) Uusi biologisesti aktiivinen peptidi ja sen valmistus
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
OA09771A (en) Asphodelus composition for increasing white blood cell count.
FI972637A0 (fi) K-ryhmän vitamiinin käyttö lisäkilpirauhasen liikatoiminnan hoitoon
IL127930A0 (en) Verapamil as a medicament for the treatment of angina
UA43389C2 (uk) Спосіб зниження рівнів кальцію у сироватці
RU95105084A (ru) Гепатопротекторное средство природного происхождения
IT1276453B1 (it) Vaccino/composizioni terapautica di helycobacter pylori, loro preparazione ed impiego.
LV5179A3 (lv) Preparats "etoksidins" teju kunga un zarnu slimibu profilaksei un arstesanai
DE68905479D1 (de) Transdermate magensafthemmende wirkstoffe zur behandlung von magen-darm-erkrankungen.

Legal Events

Date Code Title Description
FD Application lapsed